Scimago Lab
powered by Scopus
call: +1.631.629.4327
Mon-Fri 10 am - 2 pm EST


Medical Science Monitor Basic Research


eISSN: 2329-0358

Get your full text copy in PDF

Evaluation of immunoisolated insulin-secreting b3TC6-F7cells as a bioartificial pancreas

Salim N Mamujee, Daobiao Zhou, Michael Wheeler, Ivan Vacek, Anthony M Sun

Ann Transplant 1997; 2(3): 27-32

ID: 497169

Objective: To evaluate the growth and insulin secretion from microencapsulated fJTC6-F7 cells in vitro and to assessthe in vivofunction of microencapsulated cells transplanted in rats with steptozotocin (SIT) - induced diabetes. Method: Alginate-poly-L-Iysine encapsulated fJTC6-F7 cells were exposed to glucose, isobutylmethylxanthine (IBMX) and glucagon-like peptide I (7-36 amide) in a static in vitro challenge. In vivo, 2.5-3.5 x 107encapsulated cells were implanted into diabetic rats. Graft function was evaluated by monitoring blood glucose concentrations and by an intraperitoneal glucose tolerance test. Results: The cell density (number of cells per capsule) of cultured microencapsulated fJTC6-F7 cells increased almost 35-fold over a 55 day observation. period to reach a plateau of approximately 3500 cells/capsule. While insulin secretion per capsule remained unchanged over the first 21 days of culture, a 7-fold increase was observed during the last 14days of the 55 day observation period. Intraperitoneal transplantation of 3.5x 107encapsulated cells into diabetic rats resulted, within 24 hours, in reversal of hyperglycemia for up to 60 days. Post-transplantation blood glucose concentrations varied between 2 and 4 mM. Glucose clearance rates evaluated by an intraperitoneal glucose tolerance test at 30 days post-transplantation resulted in a markedly flat glucose clearance curve with blood glucose never rising above 4 mM. The glucose challenge of microencapsulated cells recovered 30 days post-transplantation resulted in a 2-fold increase in insulin response at glucose concentrations greater than 5.5 mM as compared to glucose-free media. In addition, immunostaining of recovered grafted tissue for insulin, reveals a strong presence of the peptide within the cell population. Conclusions: These data demonstrate the potential use of an immunoisolated ,B-celiline for the treatment of diabetes.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree